News
Resources
Blog
Sites
Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.
Recent Posts
The risks of counterfeit imported medicines
By Allyson Funk | April 20, 2017
A recent Wall Street Journal article laid out the serious concerns posed by potent, counterfeit prescription opioids pouring into the United States from China, Mexico and Canada. The Drug...
Read More
Medicare Monday: A guide to MedPAC’s Part B vote this week
By Allyson Funk | April 3, 2017
The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises Congress on issues related to the Medicare program, including payment, access to and quality...
Read More
ICYMI: What the experts are saying about importation
By Allyson Funk | March 23, 2017
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have...
Read More
Medicare Monday: Billing code basics for biologics in Part B
By Allyson Funk | March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would...
Read More
How drug importation schemes could increase U.S. law enforcement burdens
By Allyson Funk | March 16, 2017
In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?
Read More
Why drug importation threatens patient safety
By Allyson Funk | February 28, 2017
Counterfeit drug manufacturing and trafficking is a multi-billion dollar business. Legislative proposals to allow importation of potentially counterfeit and substandard drugs into the United...
Read More
Fact Check Friday: The truth about drug importation and patient safety
By Allyson Funk | February 24, 2017
This week on Fact Check Friday, we’re discussing the truth about proposals to allow the importation of medicines from other countries and what these proposals mean for patients. MYTH: Importation...
Read More
What you don’t know about importation from Canada
By Allyson Funk | February 17, 2017
Proposals to allow the importation of prescription medicines from Canada ignore the dangerous threat to patients of counterfeit and adulterated medicines. What actually happens when a patient...
Read More
Medicare Monday: Negotiation in Medicare Part D works
By Allyson Funk | December 12, 2016
Earlier this year, we highlighted a new QuintilesIMS Institute research brief that, for the first time, looked at Part D costs after accounting for rebates.
Read More
Medicare Monday: Beware! Scary proposed changes to Medicare are out there
By Allyson Funk | October 31, 2016
This Halloween, beware of the spooky proposals some have put forward to change how Medicare covers prescription medicines for seniors and people living with disabilities. Tricks like these are no...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
